Istituto San Raffaele

Running trials

• Recruiting

  A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

  NCT07286149· Phase 1/2· Source

• Recruiting

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· Phase 3· Source

• Recruiting

  MITO 31- A phase II trial of Olaparib in patients with recurrent ovarian cancer wild type for germline and somatic BRCA 1 and 2 genes: The MITO 31 translational study.

  NCT04091204· Phase 2· Source

• Recruiting

  Anti-viral action against Type 1 diabetes autoimmunity GPPAD-05-AVAnT1A

  2023-507348-35-00· Phase 4· Source

• Active, not recruiting

  Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

  NCT05840211· Phase 3· Source

• Not yet recruiting

  Prospective Phase II study on Safety and Efficacy of Fludarabine plus Treosulfan (14g) (FT14) conditioning regimen for allogeneic Stem Cell Transplantation (allo-SCT) in Acute Myeloid Leukemia (AML) patients (≥40 <65years)

  2024-520326-11-00· Phase 2· Source

• Not yet recruiting

  A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)

  2024-519031-42-00· Phase 3· Source

• Active, not recruiting

  A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy

  NCT03767244· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukemia1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Type 1 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Efficacy and Safety of REL-1017 for Major Depressive Disorder

  2023-507399-27-00· Phase 3· Source

• Completed

  No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis

  2024-515470-26-00· Phase 2· Source

• Completed

  Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

  NCT06059547· Phase 2· Source

• Completed

  A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression.

  2023-508163-74-00· Phase 3· Source

• Active, not recruiting

  Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

  NCT02475681· Phase 3· Source